Ann: Final HER-Vaxx Phase 2 Trial Overall Survival Results, page-86

Well its a solid validation of what was once an unheard of treatment for cancer

> Non Toxic & no side effects
> Likely much much cheaper to make
> Likely much less after care / administrative medication time
> Total overall care cost probably less than 30% of the current SoC ( synthetically produced antibodies )
> In theory it should reinforce the interest in and subscription to a "Game Changing " platform of B Cell treatment
> Whats the IP worth ???? Who knows ..... quite a bit I imagine.

Will people be caught short on this stock - I sincerely hope so as the knowledge & IP fundamentals behind IMU are
quite remarkable.

Meanwhile the short term technical analysis of the share price seems to have dominated the conversation for quite a while

I wonder what a patient who should have been dead a year ago , but is still alive and kicking thinks about the charts ?

LOL

Meanwhile a bit of a lesson on roasting pigs over the coals .

Could be relevant for large shorters or recent dumpers of the stock